0
(Adds details in paragraphs 2 and 3) Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease. The drug, Povofortay,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)